Sonnet Biotherapeutics Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Sonnet BioTherapeutics Chief Medical Officer Richard T. Kenney reported significant changes in his beneficial ownership following the company's merger with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics' Chief Business Officer, Stephen J. McAndrew, reported the disposition of 6,446 common shares following the company's business combination with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics CFO Donald J. Griffith reported the disposition of all 10,375 common shares following the company's merger into Hyperliquid Strategies Inc.
Sonnet BioTherapeutics Director Lori McNeill exchanged 4,394 common shares for Hyperliquid Strategies stock and CVRs following a business combination.
Sonnet BioTherapeutics Director Susan Dexter reported the disposition of 9,643 common shares, converting them into Hyperliquid Strategies Inc. stock and CVRs following a business combination.
Sonnet BioTherapeutics Holdings, Inc. CEO Raghu Rao reported the exchange of 22,356 vested restricted stock units for Hyperliquid Strategies Inc. common stock and CVRs following a business combination.
Director John K. Cini disposed of all his Sonnet BioTherapeutics Holdings, Inc. common stock following the company's merger into Hyperliquid Strategies Inc.
Nailesh Bhatt, a director at Sonnet BioTherapeutics Holdings, Inc., reported the disposition of 10,547 common shares following the company's merger into Hyperliquid Strategies Inc.
Sonnet BioTherapeutics Director Albert D. Dyrness reported the disposal of 4,537 common shares following the company's merger into Hyperliquid Strategies Inc.
Hyperliquid Strategies Inc. has filed a Form 425 communication regarding Sonnet BioTherapeutics Holdings, Inc. on November 18, 2025.
Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to allow more time for voting on its proposed business combination with Hyperliquid Strategies Inc.
Sonnet BioTherapeutics Holdings, Inc. filed a Rule 425 statement with the SEC on November 18, 2025, related to a business combination communication.
Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to December 2, 2025, to allow more time for voting on its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.
The requested SEC filing content was not provided, preventing a comprehensive financial and strategic analysis.
Sonnet BioTherapeutics' Chief Medical Officer, Richard T. Kenney, acquired warrants and Series 5 Preferred Stock, linked to a convertible note.
Sonnet BioTherapeutics Holdings, Inc. Director Albert D. Dyrness was granted 4,000 restricted stock units, which will vest by January 8, 2026, and now beneficially owns 4,537 shares of common stock.
Sonnet BioTherapeutics Holdings, Inc. Chief Business Officer Stephen J. McAndrew was granted 6,000 restricted stock units, which are set to vest by early 2026 or upon a change in control.
Sonnet BioTherapeutics Holdings, Inc. has granted its Interim CEO, Raghu Rao, 20,000 restricted stock units, which will vest fully by January 8, 2026, or upon a change in control.
Sonnet BioTherapeutics Holdings, Inc. Chief Financial Officer and Director Donald J. Griffith was granted 10,000 restricted stock units, increasing his beneficial ownership to 10,375 shares.
Sonnet BioTherapeutics Holdings, Inc. Director Lori McNeill reported the acquisition of 4,000 restricted stock units, increasing her beneficial ownership to 4,394 shares, as detailed in a recent Form 4 filing.
Sonnet BioTherapeutics Holdings, Inc. Director Nailesh Bhatt acquired 10,000 shares of common stock on July 11, 2025, as part of a 20,000 restricted stock unit grant.
Sonnet BioTherapeutics Holdings, Inc.'s Chief Medical Officer, Richard T. Kenney, was granted 8,000 restricted stock units, vesting by January 2026 or upon a change in control.
Sonnet BioTherapeutics Holdings, Inc.'s Chief Scientific Officer, John K. Cini, was granted 12,000 restricted stock units, vesting by January 2026 or upon a change in control.
Sonnet BioTherapeutics Holdings, Inc.'s Chief Technical Officer, Susan Dexter, was granted 8,000 restricted stock units, which are set to vest by early 2026 or upon a change in control.
Sonnet BioTherapeutics Holdings, Inc. announced a definitive agreement for a business combination with Rorschach I LLC, a newly-formed entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, to transform into Hyperliquid Strategies Inc. (HSI), a publicly listed cryptocurrency treasury company focused on HYPE tokens.
Nailesh Bhatt, a director at Sonnet BioTherapeutics, was granted 373 restricted stock units that will vest on January 1, 2025.
Susan Dexter, Chief Technical Officer of Sonnet BioTherapeutics, was granted 1,452 restricted stock units that will vest on January 1, 2025.
Lori McNeill, a director at Sonnet BioTherapeutics, was granted 373 restricted stock units on December 11, 2023, which will vest on January 1, 2025.
Director Albert Dyrness of Sonnet BioTherapeutics Holdings, Inc. was granted 373 restricted stock units on December 11, 2023, which will vest on January 1, 2025.
A Sonnet BioTherapeutics director, Raghu Rao, was granted 373 restricted stock units that will vest on January 1, 2025.